Protagenic Common Stock Total Equity from 2010 to 2024
| PTIX Stock | USD 0.73 0.08 12.31% |
Common Stock Total Equity | First Reported 1997-06-30 | Previous Quarter 1.1 K | Current Value 1.6 K | Quarterly Volatility 130.3 K |
Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 87.3 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.
Protagenic | Common Stock Total Equity |
Latest Protagenic Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Protagenic Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Protagenic Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Protagenic Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 134,636 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 260.96 | |
| Mean Deviation | 230,764 | |
| Median | 1,036 | |
| Standard Deviation | 351,345 | |
| Sample Variance | 123.4B | |
| Range | 1000K | |
| R-Value | (0.50) | |
| Mean Square Error | 99.5B | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | (39,430) | |
| Total Sum of Squares | 1.7T |
Protagenic Common Stock Total Equity History
About Protagenic Therapeutics Financial Statements
Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 1.2 K | 1.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.